Cardiac Arrests With Shockable Rhythm, Mild Therapeutic Hypothermia, Preventive Antibiotics, Ventilator-associated Pneumonia
Conditions
Keywords
ventilator-associated pneumonia, cardiac arrests with shockable rhythm, Mild therapeutic hypothermia, preventive antibiotics
Brief summary
Mild therapeutic hypothermia is currently recommended in management of cardiac arrests with shockable rhythm. In mechanically ventilated patients who were resuscitated after out-of-hospital cardiac arrests, mild therapeutic hypothermia side effects are conductive for infectious complications and especially for ventilator-associated pneumonia (VAP). Despite high incidence of VAP and other infectious complications, it is not currently recommended to use antibiotic prophylaxis on the responsible germs. Yet VAP incidence could be decreased if an antibiotic therapy was systematically given to patient treated with mild therapeutic hypothermia after a cardiac arrest. Several retrospective studies showed less infectious complications but also decreased morbidity and mortality related to these complications when antibiotic therapy was given early to patients treated with therapeutic hypothermia after cardiac arrest.
Detailed description
Multicenter add-on randomized controlled double-blind trial assessing the efficacy of preventive antibiotics amoxicillin-clavulanic acid vs placebo to prevent occurrence of early VAP after out-of-hospital cardiac arrest receiving mild therapeutic hypothermia, in addition to usual VAP prevention measures.
Interventions
DRUGAmoxicillin - clavulanic acid
Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
DRUGPlacebo
Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
Sponsors
University Hospital, Limoges
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Older than 18 years-old, intubated and mechanically ventilated after out-of-hospital resuscitated cardiac arrest secondary to shockable rhythm * Hospitalized in an ICU * Mild therapeutic hypothermia procedure (32° to 35°C) scheduled (24 to 36 hours) * Delay from ROSC to randomisation \< 6 hours * Consent from family members or emergency consent
Exclusion criteria
* Pregnancy * Out-of-hospital cardiac arrest secondary to non shockable rhythm and In-hospital cardiac arrest * Need for cardiac support by cardiopulmonary bypass * Ongoing antibiotic therapy or during the week before * Ongoing or concomitant pneumonia * Known chronic colonization with MRB * Hypersensitivity to the active substances, to any of the penicillins or to any of the excipients. * History of a severe immediate hypersensitivity reaction (e.g. anaphylaxis) to another beta-lactam agent (e.g. a cephalosporin, carbapenem or monobactam). * History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid, according to the latest version of the SmPC. * Previous lung disease * Predictable decision of early care limitation * Patient under guardianship or curatorship * Moribund patient * Participation to another trial within 30 days
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Incidence reduction of early VAP | 7 days | Incidence reduction of early VAP with short term amoxicillin-clavulanic acid in patients treated with hypothermia after out-of-hospital cardiac arrest |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Mortality | 28 days | Mortality |
| Early nosocomial infectious complications | 28 days | — |
Countries
France
Outcome results
None listed